Literature DB >> 2493403

Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval.

D R Meldrum1, A Wisot, F Hamilton, A L Gutlay, W F Kempton, D Huynh.   

Abstract

Pituitary suppression with leuprolide acetate (LA) was used before and during ovarian stimulation with human menopausal gonadotropins in 45 consecutive women having their first cycle of in vitro fertilization embryo transfer (IVF-ET). As anticipated, a low rate of cycle cancellation (6.7%) was necessary for poor responses. Follicles were allowed to develop to a larger diameter than with our prior protocol without LA. On the day of human chorionic gonadotropin (hCG), 11.5 + 0.7 follicles of at least 1.0 cm were visualized; 11.7 + 0.9 oocytes were retrieved; 67.5% fertilized and 6.7 + 0.6 normal embryos were available for transfer. Of the 3.4 + 0.1 embryos transferred per patient, 24.6% implanted. The rates of clinical pregnancy per retrieval and per stimulation were 54% and 47%, respectively, of which 23.8% aborted. Routine use of LA resulted in a highly efficient level of ongoing pregnancy per initiated cycle, and therefore may produce a superior first cycle for IVF-ET.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493403     DOI: 10.1016/s0015-0282(16)60553-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  26 in total

1.  Comparison of pregnancy rates following in vitro fertilization-embryo transfer between the donors and the recipients in a donor oocyte program.

Authors:  J H Check; K Nowroozi; J Chase; A Nazari; C Braithwaite
Journal:  J Assist Reprod Genet       Date:  1992-06       Impact factor: 3.412

2.  Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality.

Authors:  H C Liu; Y M Lai; O Davis; A S Berkeley; M Graf; J Grifo; J Cohen; Z Rosenwaks
Journal:  J Assist Reprod Genet       Date:  1992-08       Impact factor: 3.412

3.  Normal fertilization in men with high antibody sperm binding by the addition of sufficient unbound sperm in vitro.

Authors:  F Hamilton; A L Gutlay-Yeo; D R Meldrum
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-12

4.  A corpus luteum is not a prerequisite for the expression of progesterone induced blocking factor by T-lymphocytes a week after implantation.

Authors:  J H Check; J Szekeres-Bartho; P Nazari; Y Katz; M L Check
Journal:  J Assist Reprod Genet       Date:  2001-11       Impact factor: 3.412

5.  Efficiency and cost effectiveness of three protocols for gamete transfer.

Authors:  S G Awadalla; G W Randall
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-12

6.  Assisted hatching reduces the age-related decline in IVF outcome in women younger than age 43 without increasing miscarriage or monozygotic twinning.

Authors:  D R Meldrum; A Wisot; B Yee; G Garzo; L Yeo; F Hamilton
Journal:  J Assist Reprod Genet       Date:  1998-08       Impact factor: 3.412

7.  Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments.

Authors:  J M Cummins; J M Yovich; W R Edirisinghe; J L Yovich
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-12

8.  Impact of leuprolide acetate on the response to follicular stimulation for in vitro fertilization in patients with normal basal gonadotropin levels.

Authors:  R G Brzyski; G S Jones; S Oehninger; A A Acosta; C H Kruithoff; S J Muasher
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-10

9.  The utility of serum progesterone and inhibin A for monitoring natural-cycle IVF-ET.

Authors:  S R Lindheim; P L Chang; A Vidali; M Ferin; M V Sauer
Journal:  J Assist Reprod Genet       Date:  1998-10       Impact factor: 3.412

10.  Delayed embryo implantation following in vitro fertilization and embryo transfer (IVFET).

Authors:  D Tulchinsky; A Tulchinsky; V Paoletti-Falcone; H Nash; S Pazdziorko; K Brown
Journal:  J Assist Reprod Genet       Date:  1996-08       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.